title: [Carbamazepine-fluvoxamine interaction. Consequences for the carbamazepine plasma level].
abstract: The current practices concerning psychotropic drugs use plasma levels for the therapeutic adaptation and for the prevention of overdose and side effects. We observed, among two patients treated with constant dosages of carbamazepine (CBZ), that the addition of fluvoxamine (FLV) has increased significantly plasma levels of CBZ. The first patient, suffering of an affective bipolar trouble (ICD-10), was hospitalized for major depression. His admission treatment was CBZ (800 mg/day) and cyamemazine (75 mg/day). The introduction of the FLV (200 mg/day) was justified by the symptomatology. Then, plasma levels of CBZ increased progressively. No clinic or biological side effect was observed. Rapidly, CBZ oral dosages were decreased, but the plasma levels of CBZ reached the therapeutic window only when the FLV prescription was definitively stopped. The other patient was hospitalized for an acute exacerbation of a paranoiac disorder. He was treated with haloperidol for this episode. For five years, he received CBZ for neuralgia of the Trigeminus. The emergence of a depressive disorder justified a FLV treatment. From the introduction of FLV, plasma levels of CBZ were significantly increased. The reduction, then the stop of the FLV treatment, has allowed the standardization of plasma concentrations of CBZ. Three similar studies were found in the literature. The danger of this interaction was notified in two studies (one case each). Furthermore, in the third study (three cases) was put forward the hypothesis of a new therapeutic pathway. this hypothesis was suggested by the fact that these two medications were proposed independently to treat impulsive behaviors.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: CHRU Lille, Université de Lille II, Service de Psychiatrie générale.
authors.forename: O
authors.initials: O
authors.lastname: Cottencin
authors.forename: N
authors.initials: N
authors.lastname: Regnaut
authors.forename: C
authors.initials: C
authors.lastname: Thévenon-Gignac
authors.forename: P
authors.initials: P
authors.lastname: Thomas
authors.forename: M
authors.initials: M
authors.lastname: Goudemand
authors.forename: C
authors.initials: C
authors.lastname: Debruille
authors.forename: H
authors.initials: H
authors.lastname: Robert
mesh_terms: D000328:Adult; D001714:Bipolar Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D016666:Fluvoxamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010259:Paranoid Disorders / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D014277:Trigeminal Neuralgia / Q000097:blood / Q000188:drug therapy
chemical_list: D002220:Carbamazepine; D016666:Fluvoxamine
vernacular_title: Interaction carbamazépine-fluvoxamine. Conséquences sur le taux plasmatique de carbamazépine.